ReviewFrontiers in nutrition2025
Metabolic syndrome: epidemiology, mechanisms, and current therapeutic approaches.
Review in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A bibliometric analysis of the Mediterranean diet in metabolic syndrome (2015-2025).Frontiers in nutrition · 2026Pooled it
- The effect of DASH diet on components of metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials.Frontiers in nutrition · 2026Pooled it
- Mechanistic Insights into Houttuynia cordata Thunb. as a Potential Therapeutic Strategy Targeting Metabolic Disorders in Preclinical Models.Current nutrition reports · 2026Review
- The Gut-Brain Axis in Metabolic Syndrome: Emerging Mechanisms and Perspectives in Personalized Medicine.International journal of molecular sciences · 2026Review
- Article
- Special Issue "Neuroinflammation and Neurodegeneration: Molecular Mechanism and Novel Therapy".International journal of molecular sciences · 2026Article
- Article
- Predictors of metabolic syndrome among type II diabetic patients visiting public hospitals in Sidama Region, Ethiopia: unmatched case control study.BMC cardiovascular disorders · 2026Article
- Visceral Adiposity and Markers of Relative Sarcopenia in Young Adults with Normal Weight Obesity: Gender Differences.Healthcare (Basel, Switzerland) · 2026Article
- Multistate markov model analysis of metabolic syndrome progression in a community-based longitudinal cohort study.Diabetology & metabolic syndrome · 2026Article
- Review
- Antidepressant Augmentation of Antipsychotic Treatment in Schizophrenia: A Narrative Review.Medical science monitor : international medical journal of experimental and clinical research · 2026Review
- Time-of-day-dependent effects of exercise on the hepatic clock and proteome in high-fat diet-fed mice.Journal of physiology and biochemistry · 2026Article
- The Effect of Viniferin on Liver Cancer: Research Based on Network Pharmacology, Molecular Docking and Molecular Dynamics Simulation.Medical sciences (Basel, Switzerland) · 2026Article
- Metabolic Disorders and Inflammatory Bowel Diseases: Unraveling Shared Pathways and Clinical Interactions.Metabolites · 2026Review
- The Emerging Role of Mechanobiology in Connecting Metabolic and Cardiovascular Diseases: From Fundamentals to Future Therapies.Biomedicines · 2026Review
- Non-linear association of visceral adiposity index with incident diabetes: insights from a retrospective Japanese cohort study.Endocrine · 2026Article
- C-Reactive Protein and Neurological Autoimmune Diseases: Bridging the Diagnostic and Pathogenic Gap.International journal of molecular sciences · 2026Review
- Molecular Mechanisms Underlying Atherosclerosis and Current Advances in Targeted Therapeutics.International journal of molecular sciences · 2026Review
- Associations Between Triglycerides and Walking Capacity in Community-Dwelling Older Adults with Metabolic Syndrome.Diseases (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic syndrome (MetS) is a complex condition marked by central obesity, dyslipidemia, hypertension, insulin resistance, oxidative stress, and chronic inflammation. These risk factors significantly raise the risk of cardiovascular disease (CVD) through various mechanisms, leading to a public health challenge. MetS contributes to CVD through cardiometabolic derangements such as endothelial dysfunction, atherosclerosis, oxidative stress, and inflammation. Dyslipidemia, especially elevated triglycerides and reduced high-density lipo-protein (HDL) cholesterol is central to atherosclerosis. Additionally, hypertension and insulin resistance damage blood vessels, a process exacerbated by chronic inflammation and oxidative stress. Thus, managing MetS and its components through lifestyle changes like weight control, dietary improvements, exercise, and smoking cessation is essential for reducing CVD risk. Medications targeting specific risk factors, such as blood sugar, cholesterol, and blood pressure, may also be required. Raising awareness and early screening are crucial to countering MetS's impact on public health. This review provides a comprehensive overview of the mechanisms by which MetS contributes to CVD and the intricate interplay of factors and molecular pathways linking MetS to CVD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.